Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

por Auster, Oren, Finkel, Uriah, Dagan, Noa, Barda, Noam, Laufer, Alon, Balicer, Ran D., Ben-Shachar, Shay
Publicado 2022